Page last updated: 2024-10-21

hydroxyindoleacetic acid and Neuroendocrine Tumors

hydroxyindoleacetic acid has been researched along with Neuroendocrine Tumors in 54 studies

(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.

Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.

Research Excerpts

ExcerptRelevanceReference
"Urinary 5-hydroxyindoleacetic acid (5-HIAA) is an established biomarker in neuroendocrine tumors and carcinoid syndrome; however, its role in nonfunctional neuroendocrine tumors is not defined."9.30Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. ( Fisher, GA; Liyanage, N; Mirakhur, B; Pavel, ME; Phan, AT; Pitman Lowenthal, S; Vinik, AI; Wolin, EM, 2019)
"Urinary 5-hydroxyindoleacetic acid (5-HIAA) is an established biomarker in neuroendocrine tumors and carcinoid syndrome; however, its role in nonfunctional neuroendocrine tumors is not defined."5.30Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. ( Fisher, GA; Liyanage, N; Mirakhur, B; Pavel, ME; Phan, AT; Pitman Lowenthal, S; Vinik, AI; Wolin, EM, 2019)
"Serum 5-hydroxyindoleacetic acid (5-HIAA) could replace the determination of 24-h urinary 5-HIAA for diagnosis and follow-up of neuroendocrine tumors (NETs)."3.80Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker. ( Hämäläinen, E; Itkonen, O; Joenväärä, S; Markkanen, H; Renkonen, R; Sane, T; Tohmola, N, 2014)
"5-Hydroxyindoleacetic acid (5-HIAA) is used for the evaluation of neuroendocrine tumors (NETs) but currently requires a 24-hour urine collection."3.79A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). ( Mamikunian, G; O'Dorisio, TM; Tellez, MR; Vinik, AI; Woltering, EA, 2013)
"The urinary excretion of vanillylmandelic acid (VMA), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) can be increased in the presence of neuroblastic and carcinoid tumors."3.74HPLC-mass spectrometry method for quantitative detection of neuroendocrine tumor markers: vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid. ( Cardelli, P; Lionetto, L; Lostia, AM; Simmaco, M; Stigliano, A, 2008)
"The predominant histotype was carcinoid, although a few cases had malignant islet cell tumors, medullary thyroid carcinoma, Merkel cell carcinoma, or other neuroendocrine tumors."2.67Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. ( Bajetta, E; Bochicchio, AM; Buzzoni, R; Castellani, R; Celio, L; Di Bartolomeo, M; Di Leo, A; Dogliotti, L; Pilotti, S; Zilembo, N, 1993)
"Neuroendocrine tumors are increasingly diagnosed, either incidentally as part of screening processes, or for symptoms, which have commonly been mistaken for other disorders initially."2.53Neuroendocrine Tumors. ( Basuroy, R; Ramage, JK; Srirajaskanthan, R, 2016)
"Primary ovarian carcinoid tumors are rare neuroendocrine tumors, and can be associated with carcinoid syndrome and carcinoid heart disease."1.72A Case of Primary Insular Ovarian Carcinoid Tumor with Hyperandrogenism and Carcinoid Heart Disease. ( Al-Agha, R; Anaka, MR; Mansour, S, 2022)
"Direct-matrix derivatization in combination with LC-MS/MS is a powerful tool for the simultaneous quantification of all tryptophan-related indoles in platelet-rich plasma."1.51Quantitative Profiling of Platelet-Rich Plasma Indole Markers by Direct-Matrix Derivatization Combined with LC-MS/MS in Patients with Neuroendocrine Tumors. ( Bouma, G; de Hosson, LD; de Vries, EGE; Kats-Ugurlu, G; Kema, IP; Peters, MAM; van Faassen, M; Walenkamp, AME, 2019)
"18 patients with metastatic carcinoids who underwent 111In-pentetreotide scanning were all somatostatin receptor positive."1.29Somatostatin receptor imaging: predictive and prognostic considerations. ( Anthony, LB; Delbeke, D; Martin, W; Sandler, M, 1996)

Research

Studies (54)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's8 (14.81)18.2507
2000's11 (20.37)29.6817
2010's29 (53.70)24.3611
2020's6 (11.11)2.80

Authors

AuthorsStudies
Meyer, T1
Caplin, M2
Khan, MS1
Toumpanakis, C1
Shetty, S1
Ramage, JK2
Houchard, A1
Higgs, K1
Shah, T1
Kostiainen, I1
Karppinen, N1
Simonen, P1
Rosengård-Bärlund, M1
Lindén, R1
Tarkkanen, M1
Gordin, D1
Rapola, J1
Schalin-Jäntti, C2
Matikainen, N1
Mansour, S1
Anaka, MR1
Al-Agha, R1
van Faassen, M1
Bouma, G1
de Hosson, LD1
Peters, MAM1
Kats-Ugurlu, G1
de Vries, EGE1
Walenkamp, AME1
Kema, IP1
Gut, P1
Ruchała, M1
de Mestier, L1
Savagner, F1
Brixi, H1
Do Cao, C1
Dominguez-Tinajero, S1
Roquin, G1
Goichot, B1
Hentic, O1
Dubreuil, O1
Hautefeuille, V2
Walter, T2
Cadiot, G1
Maurel, J1
Guimbaud, R1
Lecomte, T1
Lièvre, A1
Robinson, P1
Francois, L1
Lombard-Bohas, C1
Forestier, J1
Milot, L2
Subtil, F1
Zandee, WT2
Brabander, T1
Blažević, A1
Minczeles, NS1
Feelders, RA2
de Herder, WW3
Hofland, J1
Rodríguez Laval, V1
Pavel, M1
Steffen, IG1
Baur, AD1
Dilz, LM1
Fischer, C1
Detjen, K1
Prasad, V1
Pascher, A1
Geisel, D1
Denecke, T1
Chan, DL2
Clarke, SJ1
Diakos, CI1
Roach, PJ1
Bailey, DL1
Singh, S3
Pavlakis, N1
Dixon, M1
Law, CHL1
Koujanian, S1
Beyfuss, KA1
Myrehaug, S1
Hallet, J1
Lindström, M1
Tohmola, N2
Renkonen, R2
Hämäläinen, E2
Itkonen, O2
Tirosh, A1
Nilubol, N2
Patel, D1
Kebebew, E2
Pavel, ME1
Phan, AT1
Wolin, EM1
Mirakhur, B1
Liyanage, N1
Pitman Lowenthal, S1
Fisher, GA1
Vinik, AI3
Pinto, MP1
Muñoz Medel, M1
Carrillo, D1
Retamal, IN1
Bravo, ML1
Valenzuela, Y1
Nervi, B1
Sánchez, C1
Galindo, H1
Ibañez, C1
Peña, J1
Balmaceda, C1
Madrid, J1
Briones, J1
Torres, J1
Nilo, F1
Guarda, FJ1
Quintana, JC1
Orellana, P1
Mondaca, S1
Acevedo, F1
Vicentini, D1
Cordova-Delgado, M1
Owen, GI1
Garrido, M1
Padelli, M1
Bruno, C1
Lemarchand, J1
Vourc'h, P1
Andres, C1
Blasco, H1
Benz-de Bretagne, I1
Walsh, JS1
Newell-Price, JD1
DeBono, M1
Adaway, J1
Keevil, B2
Eastell, R1
Sen Gupta, P1
Grozinsky-Glasberg, S1
Drake, WM1
Akker, SA1
Perry, L1
Grossman, AB1
Druce, MR1
Sane, T1
Markkanen, H1
Joenväärä, S1
Dobson, R1
Cuthbertson, DJ1
Jones, J1
Valle, JW1
Chadwick, C1
Poston, GP1
Burgess, MI1
Nadler, A1
Cukier, M1
Law, CH1
Tőke, J1
Czirják, G1
Tóth, M1
Rácz, K1
Patócs, A1
Al-Efraij, K1
Aljama, MA1
Kennecke, HF1
Ardill, JE1
Armstrong, L1
Smye, M1
Doherty, R1
McCance, DR1
Johnston, BT1
Sadowski, SM1
Neychev, V1
Millo, C1
Shih, J1
Herscovitch, P1
Pacak, K1
Marx, SJ1
Jahagirdar, V1
Kamal, A1
Steeds, R1
Ayuk, J1
Kinová, S1
Kovácová, M1
Caprnda, M1
Koren, M1
Kamp, K1
van Adrichem, RC1
Basuroy, R1
Srirajaskanthan, R1
Lionetto, L1
Lostia, AM1
Stigliano, A1
Cardelli, P1
Simmaco, M1
Korse, CM1
Bonfrer, JM1
Aaronson, NK1
Hart, AA1
Taal, BG1
O'Toole, D1
Grossman, A1
Gross, D1
Delle Fave, G1
Barkmanova, J1
O'Connor, J1
Pape, UF1
Plöckinger, U1
Manickum, T1
Berković, MC1
Jokić, M1
Marout, J1
Radosević, S1
Zjacić-Rotkvić, V1
Kapitanović, S1
Woltering, EA2
Warner, RR1
O'Dorisio, TM2
Wiseman, GA1
Coppola, D1
Go, VL1
Figueroa-Vega, N1
Díaz, A1
Adrados, M1
Alvarez-Escolá, C1
Paniagua, A1
Aragonés, J1
Martín-Pérez, E1
Leskela, S1
Moreno-Otero, R1
González-Amaro, R1
Marazuela, M1
Gregersen, T1
Grønbæk, H1
Worsøe, J1
Schlageter, V1
Laurberg, S1
Krogh, K1
Tellez, MR1
Mamikunian, G1
Monteleone, M1
Naccarato, A1
Sindona, G1
Tagarelli, A1
Piette, C1
Polus, M1
Louis, E1
De Block, CE1
Colpin, G1
Thielemans, K1
Coopmans, W2
Bogers, JJ1
Pelckmans, PA1
Van Marck, EA1
Van Hoof, V1
Martin, M1
De Leeuw, IH1
Bouillon, R2
Van Gaal, LF1
Søndenaa, K1
Sen, J1
Heinle, F1
Fjetland, L1
Gudlaugsson, E1
Syversen, U1
Rorstad, O1
Ferolla, P1
Faggiano, A1
Mansueto, G1
Avenia, N1
Cantelmi, MG1
Giovenali, P1
Del Basso De Caro, ML1
Milone, F1
Scarpelli, G1
Masone, S1
Santeusanio, F1
Lombardi, G1
Angeletti, G1
Colao, A1
Nold, R1
Frank, M1
Kajdan, U1
Trost, U1
Klose, KJ1
Arnold, R1
Jacobsen, MB1
Hanssen, LE1
Bajetta, E2
Zilembo, N2
Di Bartolomeo, M2
Di Leo, A1
Pilotti, S1
Bochicchio, AM1
Castellani, R1
Buzzoni, R1
Celio, L2
Dogliotti, L1
Anthony, LB1
Martin, W1
Delbeke, D1
Sandler, M1
Nobels, FR1
Kwekkeboom, DJ1
Schoenmakers, CH1
Lindemans, J1
Krenning, EP1
Lamberts, SW1
Baudin, E1
Bidart, JM1
Rougier, P1
Lazar, V1
Ruffié, P1
Ropers, J1
Ducreux, M1
Troalen, F1
Sabourin, JC1
Comoy, E1
Lasser, P1
DeBaere, T1
Schlumberger, M1
Brannan, SO1
Lessan, NG1
Hiscott, P1
Damato, B1
Ferrari, L1
Martinetti, A1
Procopio, G1
Artale, S1
Seregni, E1
Bombardieri, E1
Eriksson, B1
Oberg, K1
Stridsberg, M1
Ricci, S1
Antonuzzo, A1
Galli, L1
Ferdeghini, M1
Bodei, L1
Orlandini, C1
Conte, PF1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase IV, Multicentre, Open Label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients Receiving Deep Subcutaneo[NCT02075606]Phase 450 participants (Actual)Interventional2014-05-31Completed
Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors[NCT02826928]116 participants (Actual)Interventional2016-10-26Completed
Overall Survival and Progression Free Survival of Patients With Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV[NCT03998332]132 participants (Actual)Observational2002-01-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Subjects Alive and Progression Free at One Year

"Subjects underwent CT or MRI scans at baseline and Week 53. Progression was assessed by investigators using RECIST v1.1. The best overall response to study treatment is the highest time point response achieved by the subject and was assessed as a complete response, partial response, stable disease, progressive disease or non evaluable. For analysis of PFS, event dates were assigned to the first time that progressive disease was noted or the date of death. In case of progressive disease followed by death, the first event was considered in the analysis. Censoring dates were defined in subjects with no progressive disease or death before end of study.~At one year (end of study), the mean percentage of subjects who were alive and progression free, as calculated using the Kaplan-Meier method, is reported by CTC presence and overall." (NCT02075606)
Timeframe: From baseline up to Week 53.

Interventionpercentage of subjects (Mean)
CTC Presence at Baseline69.00
No CTC Presence at Baseline67.75
Lanreotide Autogel66.43

Assessment of Clinical Symptomatic Response

"This endpoint was assessed using 2 efficacy variables:~CTCs, enumerated at baseline and Weeks 5, 17, 25, 53~Clinical symptomatic response, assessed by the use of symptom reporting~Subjects recorded 24-hour symptom frequency and severity for 7 days prior to first treatment (baseline), throughout the study, and up to 28 days following final drug administration. Symptoms were recorded by answering predetermined questions on the interactive voice response system (IVRS).~Subjects were considered to have a clinical symptomatic response between baseline and last study visit if any 1 of the following criteria were fulfilled: the average number of episodes of diarrhoea decreased by at least 50%, the average number of episodes of flushing decreased by at least 50%, the mode severity of flushing decreased by at least 1 level. Clinical symptomatic response was assessed as a qualitative variable (Yes/No) and reported according to CTC presence at baseline and overall." (NCT02075606)
Timeframe: From baseline up to Week 53.

,,
InterventionPercentage of Subjects (Number)
Clinical Symptomatic Response = Yes(2)Clinical Symptomatic Response = No(3)
CTC Presence at Baseline77.822.2
Lanreotide Autogel87.512.5
No CTC Presence at Baseline95.54.5

Mean Change From Baseline in Number of Episodes of Diarrhoea and Flushing

"The effect of lanreotide Autogel on the symptoms of diarrhoea and flushing in subjects was assessed through subject reporting of symptoms every 24-hours for the 7 days prior to treatment (baseline), for the first 16 weeks and on days 11 to 17 after each subsequent injection interval. After the final study drug injection at Week 49, subjects provided 24-hour symptom frequency on days 11 to 28 (up to Week 53). Symptom frequency was recorded by answering predetermined questions on the IVRS.~Mean change from baseline in frequency (number of episodes) of diarrhoea and flushing are described at Visit 2 (average number of episodes in Week 1) and at Visit 14 (average number of episodes over days 11 to 17 after Week 49 injection and over days 11 to 28 after Week 49 injection) by CTC presence at baseline and overall. A negative change indicates an improvement in symptoms from baseline." (NCT02075606)
Timeframe: From baseline up to Week 53.

Interventionnumber of episodes (Mean)
Diarrhoea: Visit 2 (daily)Flushing: Visit 2 (daily)
Missing CTC Status at Baseline0.380.00

Mean Change From Baseline in Number of Episodes of Diarrhoea and Flushing

"The effect of lanreotide Autogel on the symptoms of diarrhoea and flushing in subjects was assessed through subject reporting of symptoms every 24-hours for the 7 days prior to treatment (baseline), for the first 16 weeks and on days 11 to 17 after each subsequent injection interval. After the final study drug injection at Week 49, subjects provided 24-hour symptom frequency on days 11 to 28 (up to Week 53). Symptom frequency was recorded by answering predetermined questions on the IVRS.~Mean change from baseline in frequency (number of episodes) of diarrhoea and flushing are described at Visit 2 (average number of episodes in Week 1) and at Visit 14 (average number of episodes over days 11 to 17 after Week 49 injection and over days 11 to 28 after Week 49 injection) by CTC presence at baseline and overall. A negative change indicates an improvement in symptoms from baseline." (NCT02075606)
Timeframe: From baseline up to Week 53.

,,
Interventionnumber of episodes (Mean)
Diarrhoea: Visit 2 (daily)Diarrhoea: Visit 14 (days 11-17)Diarrhoea: Visit 14 (days 11-28)Flushing: Visit 2 (daily)Flushing: Visit 14 (days 11-17)Flushing: Visit 14 (days 11-28)
CTC Presence at Baseline-0.66-1.91-2.15-1.76-3.37-3.49
Lanreotide Autogel-0.42-1.18-1.30-1.43-2.88-2.79
No CTC Presence at Baseline-0.27-0.64-0.63-1.25-2.51-2.23

Mode Symptom Severity of Episodes of Flushing

The effect of lanreotide Autogel on the mode severity of flushing was assessed through subject reporting of symptoms every 24-hours for the 7 days prior to treatment (baseline), for the first 16 weeks and on days 11 to 17 after each subsequent injection interval until Week 49. After the final study drug injection at Week 49, subjects provided 24-hour symptom severity on days 11 to 28 (up to Week 53). Symptom severity was recorded by answering predetermined questions on the IVRS using a three-point system (mild, moderate or severe). The mode (most frequent) intensity of flushing are reported at baseline and at Visit 14 (average number of episodes over days 11 to 17 after Week 49 injection and over days 11 to 28 after Week 49 injection). Percentages of subjects in each severity category are based on the number of subjects in the analysis set with available responses. Data is presented according to CTC presence at baseline and overall. (NCT02075606)
Timeframe: From baseline up to Week 53.

,,
Interventionpercentage of subjects (Number)
No flushing: BaselineMild: BaselineModerate: BaselineSevere: BaselineNo flushing: Visit 14 (days 11-17)Mild: Visit 14 (days 11-17)Moderate: Visit 14 (days 11-17)Severe: Visit 14 (days 11-17)No flushing: Visit 14 (days 11-28)Mild: Visit 14 (days 11-28)Moderate: Visit 14 (days 11-28)Severe: Visit 14 (days 11-28)
CTC Presence at Baseline22.727.345.54.537.543.818.80.013.360.026.70.0
Lanreotide Autogel14.038.046.02.032.445.921.60.023.555.917.62.9
No CTC Presence at Baseline0.050.050.00.028.647.623.80.031.652.610.55.3

Mode Symptom Severity of Episodes of Flushing

The effect of lanreotide Autogel on the mode severity of flushing was assessed through subject reporting of symptoms every 24-hours for the 7 days prior to treatment (baseline), for the first 16 weeks and on days 11 to 17 after each subsequent injection interval until Week 49. After the final study drug injection at Week 49, subjects provided 24-hour symptom severity on days 11 to 28 (up to Week 53). Symptom severity was recorded by answering predetermined questions on the IVRS using a three-point system (mild, moderate or severe). The mode (most frequent) intensity of flushing are reported at baseline and at Visit 14 (average number of episodes over days 11 to 17 after Week 49 injection and over days 11 to 28 after Week 49 injection). Percentages of subjects in each severity category are based on the number of subjects in the analysis set with available responses. Data is presented according to CTC presence at baseline and overall. (NCT02075606)
Timeframe: From baseline up to Week 53.

Interventionpercentage of subjects (Number)
No flushing: BaselineMild: BaselineModerate: BaselineSevere: Baseline
Missing CTC Status at Baseline1000.00.00.0

Percentage of Subjects With Time Point Responses According to Response Evaluation Criteria in Solid Tumours (RECIST) Assessments at Weeks 25 and 53

"Subjects underwent Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scans at baseline, Visit 8 (Week 25) and Visit 15 (Week 53). Progression was assessed by investigators using RECIST v1.1, and classified as a complete response, partial response, stable disease, progressive disease or non evaluable.~The time point responses at Week 25 and Week 53 were analysed by CTC presence at baseline and overall. The percentage of subjects within each response category are presented. Percentages are based on the number of subjects in the concerned population with available responses." (NCT02075606)
Timeframe: Week 25 and Week 53.

,,
Interventionpercentage of subjects (Number)
Week 25: Complete ResponseWeek 25: Partial ResponseWeek 25: Stable DiseaseWeek 25: Progressive DiseaseWeek 25: Non evaluableWeek 53: Complete ResponseWeek 53: Partial ResponseWeek 53: Stable DiseaseWeek 53: Progressive DiseaseWeek 53: Non evaluable
CTC Presence at Baseline0.018.272.79.10.00.06.766.726.70.0
Lanreotide Autogel0.013.073.913.00.00.05.464.929.70.0
No CTC Presence at Baseline0.08.375.016.70.00.04.563.631.80.0

QoL Questionnaire: EORTC QLQ-G.I.NET21

The effect of lanreotide Autogel treatment on QoL was assessed using the EORTC QLQ-G.I.NET21 at baseline, Weeks 13 (Visit 5), 25 (Visit 8) and 53 (Visit 15/end of study). The QLQ-G.I.NET21 questionnaire contained 21 questions that used a 4-point scale (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much) to evaluate 3 defined multi-item symptom scales (endocrine, gastrointestinal and treatment related side effects), 2 single item symptoms (bone/muscle pain and concern about weight loss), 2 psychosocial scales (social function and disease-related worries) and 2 other single items (sexuality and communication). Each individual subscore was transformed to range from 0 to 100. Higher scores indicate worse symptoms or more problems. The mean change from baseline at each time point is reported for each of the category subscores. (NCT02075606)
Timeframe: From baseline up to Week 53.

InterventionUnits on a scale (Mean)
Endocrine symptoms: Visit 5Endocrine symptoms: Visit 8Endocrine symptoms: End of studyGastrointestinal symptoms: Visit 5Gastrointestinal symptoms: Visit 8Gastrointestinal symptoms: End of studyTreatment symptoms: Visit 5Treatment symptoms: Visit 8Treatment symptoms: End of studySocial function: Visit 5Social function: Visit 8Social function: End of studyDisease related worries: Visit 5Disease related worries: Visit 8Disease related worries: End of studyMuscle/Bone pain: Visit 5Muscle/Bone pain: Visit 8Muscle/Bone pain: End of studySexual function: Visit 5Sexual function: Visit 8Sexual function: End of studyInformation/communication function: Visit 5Information/communication function: Visit 8Information/communication function: End of studyBody image: Visit 5Body image: Visit 8Body image: End of study
Lanreotide Autogel-15.4-17.0-16.02.11.21.01.27.612.0-11.3-6.5-4.5-14.1-15.9-12.2-7.9-6.5-11.8-5.6-8.9-13.3-8.5-3.7-5.60.91.9-1.0

Quality of Life (QoL) Questionnaire: European Organisation for Research and Treatment of Cancer (EORTC) QoL Questionnaire (QLQ)-C30

"The effect of lanreotide Autogel treatment on QoL was assessed using the EORTC QLQ-C30 at baseline, Weeks 13 (Visit 5), 25 (Visit 8) and 53 (Visit 15/end of study). The 30 item scale is divided into 9 multi item scales (including 5 functional scales, 1 global health status/QoL scale and 3 general symptom scales) and 6 single items. Possible answers to the first 28 items (all items except the 2 concerning global quality of life) go from 1 (Not at all) to 4 (Very much). The answers for the 2 last questions (Q29- 30) go from 1 (Very poor) to 7 (Excellent). All of the scales and single-item measures range in score from 0 to 100. For multi-item scales, the raw score will be calculated by the addition of item responses divided by the number of items. Higher scores for global health and functional domains indicate a better QoL, while higher symptom scores indicate worse symptoms.~The mean change from baseline at each time point is reported for each of the category subscores." (NCT02075606)
Timeframe: From baseline up to Week 53.

InterventionUnits on a scale (Mean)
Physical functioning: Visit 5Physical functioning: Visit 8Physical functioning: End of studyRole functioning: Visit 5Role functioning: Visit 8Role functioning: End of studyEmotional functioning: Visit 5Emotional functioning: Visit 8Emotional functioning: End of studyCognitive functioning: Visit 5Cognitive functioning: Visit 8Cognitive functioning: End of studySocial functioning: Visit 5Social functioning: Visit 8Social functioning: End of studyGlobal QoL: Visit 5Global QoL: Visit 8Global QoL: End of studyFatigue: Visit 5Fatigue: Visit 8Fatigue: End of studyNausea and vomiting: Visit 5Nausea and vomiting: Visit 8Nausea and vomiting: End of studyPain: Visit 5Pain: Visit 8Pain: End of studyDyspnoea: Visit 5Dyspnoea: Visit 8Dyspnoea: End of studyInsomnia: Visit 5Insomnia: Visit 8Insomnia: End of studyAppetite loss: Visit 5Appetite loss: Visit 8Appetite loss: End of studyConstipation: Visit 5Constipation: Visit 8Constipation: End of studyDiarrhoea: Visit 5Diarrhoea: Visit 8Diarrhoea: End of studyFinancial difficulties: Visit 5Financial difficulties: Visit 8Financial difficulties: End of study
Lanreotide Autogel1.22.01.91.33.2-1.46.14.31.1-0.91.5-2.410.04.53.912.57.44.3-4.4-6.3-4.2-4.2-1.4-0.9-7.9-2.31.8-3.51.0-4.8-6.3-5.7-2.9-0.9-6.5-0.01.9-1.01.9-18.5-12.7-10.8-6.7-4.0-1.0

Reviews

7 reviews available for hydroxyindoleacetic acid and Neuroendocrine Tumors

ArticleYear
Prognostic and predictive biomarkers in neuroendocrine tumours.
    Critical reviews in oncology/hematology, 2017, Volume: 113

    Topics: Biomarkers, Tumor; Chromogranin A; Epigenesis, Genetic; Humans; Hydroxyindoleacetic Acid; Ki-67 Anti

2017
[Significance of biochemical markers in the diagnosis of neuroendocrine tumours and for the follow-up of patients].
    Orvosi hetilap, 2014, Nov-09, Volume: 155, Issue:45

    Topics: 5-Hydroxytryptophan; Biomarkers, Tumor; Chorionic Gonadotropin; Chromogranins; Glucagon; Humans; Hyd

2014
Neuroendocrine Tumors.
    Gastroenterology clinics of North America, 2016, Volume: 45, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Chromogranin A; Digestive System Surgical Pr

2016
[Pathological implications in the neuroendocrine gastrointestinal system].
    Revue medicale de Liege, 2002, Volume: 57, Issue:8

    Topics: Carcinoid Tumor; Combined Modality Therapy; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacetic

2002
Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract.
    Journal of surgical oncology, 2005, Mar-01, Volume: 89, Issue:3

    Topics: Biomarkers, Tumor; Carcinoid Heart Disease; Carcinoid Tumor; Chromogranin A; Chromogranins; Gastroin

2005
The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers.
    Journal of endocrinological investigation, 2008, Volume: 31, Issue:3

    Topics: Biomarkers; Biomarkers, Tumor; Chromogranin A; Genetic Markers; Humans; Hydroxyindoleacetic Acid; Ne

2008
Tumor markers in neuroendocrine tumors.
    Digestion, 2000, Volume: 62 Suppl 1

    Topics: Biomarkers, Tumor; Chromogranins; Humans; Hydroxyindoleacetic Acid; Immunohistochemistry; Neuroendoc

2000

Trials

6 trials available for hydroxyindoleacetic acid and Neuroendocrine Tumors

ArticleYear
Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours.
    Journal of neuroendocrinology, 2022, Volume: 34, Issue:4

    Topics: Adult; Biomarkers, Tumor; Disease Progression; Humans; Hydroxyindoleacetic Acid; Neoplastic Cells, C

2022
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    The oncologist, 2019, Volume: 24, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chromogranin A; Female; Fo

2019
Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors.
    Scandinavian journal of gastroenterology, 2011, Volume: 46, Issue:7-8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cecum; Chromogra

2011
Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial.
    Journal of internal medicine, 1995, Volume: 237, Issue:3

    Topics: Adaptation, Psychological; Adult; Aged; Biomarkers, Tumor; Double-Blind Method; Female; Gastrointest

1995
Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.
    Cancer, 1993, Nov-15, Volume: 72, Issue:10

    Topics: Adult; Aged; Biomarkers, Tumor; Carcinoid Tumor; Drug Administration Schedule; Female; Fever; Humans

1993
Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoid Tumor;

2000

Other Studies

41 other studies available for hydroxyindoleacetic acid and Neuroendocrine Tumors

ArticleYear
Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.
    Endocrine, 2022, Volume: 77, Issue:1

    Topics: Biomarkers; Carcinoid Heart Disease; Carcinoid Tumor; Cross-Sectional Studies; Humans; Hydroxyindole

2022
A Case of Primary Insular Ovarian Carcinoid Tumor with Hyperandrogenism and Carcinoid Heart Disease.
    The American journal of case reports, 2022, Oct-01, Volume: 23

    Topics: Adult; Carcinoid Heart Disease; Carcinoid Tumor; Chromogranin A; Chromogranins; Female; Humans; Hydr

2022
Quantitative Profiling of Platelet-Rich Plasma Indole Markers by Direct-Matrix Derivatization Combined with LC-MS/MS in Patients with Neuroendocrine Tumors.
    Clinical chemistry, 2019, Volume: 65, Issue:11

    Topics: 5-Hydroxytryptophan; Adult; Aged; Biomarkers, Tumor; Chromatography, Liquid; Female; Humans; Hydroxy

2019
Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues.
    Neuro endocrinology letters, 2019, Volume: 40, Issue:7-8

    Topics: Aged; Antineoplastic Agents, Hormonal; Female; Humans; Hydroxyindoleacetic Acid; Intestinal Neoplasm

2019
Plasmatic and Urinary 5-Hydroxyindolacetic Acid Measurements in Patients With Midgut Neuroendocrine Tumors: A GTE Study.
    The Journal of clinical endocrinology and metabolism, 2021, 03-25, Volume: 106, Issue:4

    Topics: Aged; Biomarkers, Tumor; Female; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacetic Acid; Male;

2021
Value of a patient-reported-outcome measure of carcinoid syndrome symptoms.
    European journal of endocrinology, 2021, Volume: 184, Issue:5

    Topics: Aged; Cohort Studies; Female; Food; France; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcin

2021
Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.
    The Journal of clinical endocrinology and metabolism, 2021, 08-18, Volume: 106, Issue:9

    Topics: Aged; Aged, 80 and over; Cohort Studies; Diarrhea; Drug Resistance, Neoplasm; Female; Humans; Hydrox

2021
Mesenteric Fibrosis in Midgut Neuroendocrine Tumors: Functionality and Radiological Features.
    Neuroendocrinology, 2018, Volume: 106, Issue:2

    Topics: Aged; Cohort Studies; Female; Fibrosis; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacetic Acid

2018
Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
    Annals of surgical oncology, 2018, Volume: 25, Issue:6

    Topics: Aged; Cytoreduction Surgical Procedures; Embolization, Therapeutic; Female; Hepatectomy; Humans; Hyd

2018
Comparison of serum serotonin and serum 5-HIAA LC-MS/MS assays in the diagnosis of serotonin producing neuroendocrine neoplasms: A pilot study.
    Clinica chimica acta; international journal of clinical chemistry, 2018, Volume: 482

    Topics: Chromatography, Liquid; Humans; Hydroxyindoleacetic Acid; Neuroendocrine Tumors; Pilot Projects; Ref

2018
Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2018, Volume: 24, Issue:8

    Topics: Adult; Aged; Disease Progression; Female; Humans; Hydroxyindoleacetic Acid; Intestinal Neoplasms; In

2018
Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective.
    Hormones & cancer, 2019, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Chile; Chromogranin A; Female; Humans; Hydroxyindoleacetic Acid; Inc

2019
[Determination of thresholds values for platelet serotonin and urinary 5-HIAA concentrations for the biological diagnosis of digestive neuroendocrine tumors].
    Annales de biologie clinique, 2019, 04-01, Volume: 77, Issue:2

    Topics: Adult; Aged; Biomarkers; Blood Chemical Analysis; Blood Platelets; Cohort Studies; Digestive System

2019
Circulating serotonin and bone density, structure, and turnover in carcinoid syndrome.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:7

    Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Case-Contro

2013
Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
    Clinical endocrinology, 2014, Volume: 80, Issue:2

    Topics: Absorptiometry, Photon; Aged; Bone Density; Female; Humans; Hydroxyindoleacetic Acid; Linear Models;

2014
Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker.
    Clinica chimica acta; international journal of clinical chemistry, 2014, Jan-20, Volume: 428

    Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Female; Humans; Hydroxyindoleacetic Acid; Male; Mass Spe

2014
Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease.
    Neuroendocrinology, 2014, Volume: 99, Issue:2

    Topics: Aged; Aged, 80 and over; Biomarkers; Carcinoid Heart Disease; Echocardiography; Feasibility Studies;

2014
Hepatic parenchymal preserving technique in the management of diffuse bilateral neuroendocrine tumour liver metastases: a feasible approach.
    Canadian journal of surgery. Journal canadien de chirurgie, 2014, Volume: 57, Issue:2

    Topics: Adult; Aged; Chromogranin A; Feasibility Studies; Female; Hepatectomy; Humans; Hydroxyindoleacetic A

2014
Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
    Cancer medicine, 2015, Volume: 4, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Chromogranin A;

2015
Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
    QJM : monthly journal of the Association of Physicians, 2016, Volume: 109, Issue:2

    Topics: Adult; Biomarkers, Tumor; Chromogranin A; Diagnosis, Differential; Female; Humans; Hydroxyindoleacet

2016
Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Feb-20, Volume: 34, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Chromogranin A; Female; Humans; Hydroxyindoleacetic Acid; Intestinal

2016
Metastatic small bowel neuroendocrine tumour with bilateral carcinoid heart disease.
    BMJ case reports, 2016, Feb-03, Volume: 2016

    Topics: Carcinoid Heart Disease; Chromogranin A; Endocarditis; Fatal Outcome; Female; Humans; Hydroxyindolea

2016
[Management of treatment in patients with neuroendocrine neoplasmas of digestive tract].
    Vnitrni lekarstvi, 2015, Volume: 61, Issue:12 Suppl 5

    Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Chromogranin A; Endoscopy, Digestive System; Female

2015
Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
    European journal of endocrinology, 2016, Volume: 175, Issue:5

    Topics: Aged; Biomarkers, Tumor; Female; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacetic Acid; Male;

2016
HPLC-mass spectrometry method for quantitative detection of neuroendocrine tumor markers: vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid.
    Clinica chimica acta; international journal of clinical chemistry, 2008, Volume: 398, Issue:1-2

    Topics: Biomarkers, Tumor; Calibration; Carcinoid Tumor; Chromatography, High Pressure Liquid; Homovanillic

2008
Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
    Neuroendocrinology, 2009, Volume: 89, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoid Tumor; Chromogranin A; Female; Follow-U

2009
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers.
    Neuroendocrinology, 2009, Volume: 90, Issue:2

    Topics: Biomarkers; Chromogranin A; Fasting; Gastrinoma; Humans; Hydroxyindoleacetic Acid; Hypoglycemia; Ins

2009
Simultaneous analysis of neuroendocrine tumor markers by HPLC-electrochemical detection.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Dec-15, Volume: 877, Issue:32

    Topics: Adrenal Gland Neoplasms; Adult; Biomarkers, Tumor; Child; Child, Preschool; Chromatography, High Pre

2009
IL-2 -330 T/G SNP and serum values-potential new tumor markers in neuroendocrine tumors of the gastrointestinal tract and pancreas (GEP-NETs).
    Journal of molecular medicine (Berlin, Germany), 2010, Volume: 88, Issue:4

    Topics: Adult; Aged; Alleles; Biomarkers, Tumor; Cytokines; Female; Gastrointestinal Neoplasms; Genetic Pred

2010
NANETS consensus guidelines for the diagnosis of neuroendocrine tumor.
    Pancreas, 2010, Volume: 39, Issue:6

    Topics: Biomarkers, Tumor; Chromogranin A; Humans; Hydroxyindoleacetic Acid; Neuroendocrine Tumors

2010
The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors.
    Endocrine-related cancer, 2010, Volume: 17, Issue:4

    Topics: Angiopoietin-1; Angiopoietin-2; Chemotaxis; Chromogranin A; Digestive System Neoplasms; Female; Flow

2010
A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
    Pancreas, 2013, Volume: 42, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Chromogranin A; Disease Progression; Fasting; Female; Ga

2013
A reliable and simple method for the assay of neuroendocrine tumor markers in human urine by solid-phase microextraction-gas chromatography-triple quadrupole mass spectrometry.
    Analytica chimica acta, 2013, Jan-08, Volume: 759

    Topics: Adult; Biomarkers, Tumor; Female; Gas Chromatography-Mass Spectrometry; Homovanillic Acid; Humans; H

2013
Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes.
    Diabetes care, 2004, Volume: 27, Issue:6

    Topics: Autoantibodies; Biomarkers, Tumor; Chromogranin A; Chromogranins; Diabetes Mellitus, Type 1; Enteroc

2004
Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report.
    World journal of surgery, 2004, Volume: 28, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Chromogranin A; Chromogranins; Female; Humans; Hydroxyindoleacetic A

2004
[Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha].
    Zeitschrift fur Gastroenterologie, 1994, Volume: 32, Issue:4

    Topics: Biomarkers, Tumor; Combined Modality Therapy; Female; Gastrinoma; Gastrins; Gastrointestinal Neoplas

1994
Somatostatin receptor imaging: predictive and prognostic considerations.
    Digestion, 1996, Volume: 57 Suppl 1

    Topics: Carcinoid Tumor; Female; Hormone Antagonists; Humans; Hydroxyindoleacetic Acid; Indium Radioisotopes

1996
Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
    The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:8

    Topics: Adult; Aged; Biomarkers, Tumor; Carcinoid Tumor; Carcinoma, Medullary; Carcinoma, Small Cell; Chromo

1997
Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors.
    The Journal of clinical endocrinology and metabolism, 1999, Volume: 84, Issue:1

    Topics: Adult; Aged; Calcitonin; Chorionic Gonadotropin, beta Subunit, Human; Female; Hormones; Humans; Hydr

1999
A choroidal amyloid-rich neuroendocrine tumor: initial manifestation of Cushing syndrome.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1999, Volume: 117, Issue:8

    Topics: Amyloidosis; Choroid Neoplasms; Cushing Syndrome; Humans; Hydroxyindoleacetic Acid; Male; Middle Age

1999
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
    Cancer, 1999, Sep-01, Volume: 86, Issue:5

    Topics: Biomarkers; Carcinoembryonic Antigen; Chromogranin A; Chromogranins; Female; Humans; Hydroxyindoleac

1999